WO1993013065A1 - Derive de proline - Google Patents

Derive de proline Download PDF

Info

Publication number
WO1993013065A1
WO1993013065A1 PCT/JP1992/001711 JP9201711W WO9313065A1 WO 1993013065 A1 WO1993013065 A1 WO 1993013065A1 JP 9201711 W JP9201711 W JP 9201711W WO 9313065 A1 WO9313065 A1 WO 9313065A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
pyrrolidine
prolyl
phenoxyacetyl
compound
Prior art date
Application number
PCT/JP1992/001711
Other languages
English (en)
Japanese (ja)
Inventor
Koji Kobayashi
Hiroyuki Abe
Katsuo Toide
Itsuo Uchida
Original Assignee
Japan Tobacco Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc. filed Critical Japan Tobacco Inc.
Priority to US08/026,311 priority Critical patent/US5506256A/en
Publication of WO1993013065A1 publication Critical patent/WO1993013065A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention relates to a proline compound having a prolyl endopeptidase inhibitory activity, and is used in the field of medicine.
  • Prolyl endopeptidase (EC. 3. 4.21.26) is an enzyme that acts on peptides containing proline and is known to specifically cleave the carboxyl group side of proline.
  • This enzyme acts on neurotransmitters such as thyrotropin-releasing hormone (TRH), substance P, and neurotensin, and also acts on vasobresin, which is thought to be involved in learning and memory processes. It is known to decompose and inactivate them.
  • TRH thyrotropin-releasing hormone
  • substance P substance P
  • neurotensin and also acts on vasobresin, which is thought to be involved in learning and memory processes. It is known to decompose and inactivate them.
  • amyloid Proteins have been shown to play an essential role in the development of Alzheimer's disease by exhibiting neurotoxic effects.
  • prolylendopeptidase is a beta-amyloid cleaving enzyme from pre-amyloid cucumbers (FEBS Lett,, 260, 131-134 (1990)), or substance P suppresses the neurotoxic effects of beta-amyloid (Pro Natl. Acad. Sci. USA, 88, 7247-7251 (1991)) suggests that a prolyl endopeptidase inhibitor may be an effective therapeutic agent for Alheimer's disease.
  • the present inventors have conducted intensive studies to find a compound which has an amino acid, particularly a proline residue as a fragment, and which specifically and strongly inhibits the action of prolylendopeptidase.
  • the present inventors have found that a proline derivative represented by the following general formula [1] has a specific and potent prolyl endopeptidase inhibitory activity, and completed the present invention.
  • Honkiaki has the following general formula: (1)
  • ⁇ is 10—, 1 CHR 1— or 1 NR 2 — (where R 1 is a hydrogen atom or a heterocycle, and R 2 is a lower alkoxycarbonyl lower alkyl group); B is Or —NR 3 —CHR 4 —, wherein R 3 and R 4 are the same or different and are a hydrogen atom or a lower alkyl group;
  • W is a phenyl group, an adamantyl group, a lower alkyl group or a heterocyclic ring which may be substituted with a halogen atom, a lower alkyl group or a lower alkoxy group;
  • U is — ⁇ , 1 S—, 1 NH— or —CHR 5 — (where R 5 is a hydrogen atom or a lower alkoxycarbonyl group);
  • X is - S-, one S_ ⁇ one, -S0 2 one, a one hundred and one or one NH-;
  • D is a benzene ring or a hetero ring
  • Y and Z are the same or different and may be substituted with a hydrogen atom, a halogen atom, a fluorine atom, a lower alkyl group, an amino group, a nitro group, a hydroxyl group, a lower alkoxy group. Is a group).
  • U is —CH 2 —
  • W is an adamantyl group or a heterocycle
  • A is —CHR 1 — or 1 NR 2 — (where R 1 is a heterocycle) R 2 is a lower alkoxycarbonyl-lower alkyl group)
  • B is thiazolidine or R represents a heterocyclic ring.
  • the present invention provides a pharmaceutical composition containing the above proline derivative [1] as an active ingredient, which is useful as a prolyl lendopeptidase inhibitor.
  • “Lower alkyl group” means a straight or branched hydrocarbon chain having 1 to 5 carbon atoms, specifically, methyl, ethyl, propyl, isopropyl, butyl, sec- Butyl, tert-butyl, pentyl and the like.
  • the “lower alkoxy group” is an alkoxy group having 1 to 5 carbon atoms, specifically, a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, a butoxy group, a sec-butoxy group, a tert-butoxy group. And the like.
  • the “lower alkoxycarbonyl group” is an alkoxycarbonyl group having 2 to 6 carbon atoms, specifically, a methoxycarbonyl group, an ethoxyquincarbonyl group, a propoxycarbonyl group, an isopropoxycarbonyl group, a butoxycarbonyl group. , Sec-butoxycarbonyl group, tert_butoxycarbonyl group and the like.
  • the “lower alkoxycarbonyl lower alkyl group” is an alkyl group having 1 to 5 carbon atoms substituted by a lower alkoxycarbonyl group as described above, specifically, a methoxycarbonylmethyl group, a 2- (methoxycarbonylcarbonyl group). ) Ethyl, 3- (methoxycarbonyl) propyl, ethoxycarbonylmethyl, 2- (ethoxycarbonyl) ethyl, 3- (ethoxycarbonyl) propyl, propoxycarbonylmethyl, 2- (propoxycarbonyl) ethyl And 3- (propoxycarbonyl) propyl.
  • Halogen atoms are chlorine, bromine, fluorine and iodine.
  • a phenyl group J which may be substituted with a halogen atom, a lower alkyl group or a lower alkoxy group is a phenyl group which may be substituted with one or two halogen atoms, a lower alkyl group or an alkoxy group as described above.
  • Heterocycle refers to a saturated or unsaturated 4- to 7-membered ring containing one or more heteroatoms (nitrogen atom, oxygen atom or sulfur atom).
  • Thiofen, pyrazole, isoxabul, imidazole, oxazole, thiabour, pyridine, pyrimidine, pyrazine, azetidine, pyrrolidine, tetrahydrofuran, piperidine, piperazine, morpholine, homopiperidine, etc. 1] can be produced, for example, according to the following reaction steps.
  • R 6 is a benzyloxycarbonyl group, a tert-butoxycarbonyl group, or a 9-fluorenylmethyloxy group. It is an amino protecting group such as a carbonyl group, and may be any amino protecting group as long as it does not hinder the reaction.
  • compound [3] was obtained by subjecting compound [2] to a Wittig reaction to form an olefin. Thereafter, it can also be obtained by epoxidation with a peracid, for example, methyltrif using n-butyllithium or the like in an inert solvent such as tetrahydrofuran or getyl ether.
  • An olefin is obtained by generating the corresponding ylide from enylphosphonium halide and then reacting with compound [2] The reaction is carried out at a reaction temperature of 170 to reflux temperature as appropriate.
  • This olefin is dissolved in a solvent such as methylene chloride, benzene, hexane, or methanol at a temperature of from 120 ° C. to a reflux temperature, preferably from 0 ° C. to a room temperature.
  • the target compound [3] can be obtained by performing an epoxidation reaction using aqueous hydrogen peroxide.
  • An alcohol derivative represented by the general formula [5] is obtained.
  • the reaction with HS-R, where X is a zeo atom is carried out in the presence of tertiary amines such as triethylamine and N-methylmorpholine in the presence of methanol, 4-dioxane, N, N-dimethylformamide. This is performed in a solvent such as a solvent.
  • HO-R where is an oxygen atom
  • a solvent such as 1,4-dioxane or N, N-dimethylformamide
  • HO-R is converted to anion ⁇ ⁇ -R, and then reacts with [3].
  • the reaction with H 2 N—R where X is NH is carried out in a solvent such as methanol or 1,4-dioxane.
  • the reaction temperature is from room temperature to reflux temperature in each case.
  • the Amino protecting group R 6 of the intermediate represented by general formula (5) is removed according to known methods, which by compound condensation reaction represented by the formula (6), is also to obtain a compound (7).
  • the compound [10] can be obtained from the compound represented by the general formula [9].
  • the amino-protecting group R 6 is, for example, a tert-butoxycarbonyl group (B oc group)
  • removal of the intermediate represented by the formula [5] or [9] can be carried out by a known method.
  • the thus obtained deprotected product is subjected to a condensation reaction with the compound [6] by a conventional method to obtain the amino acid derivative [7] or [10].
  • Q means a W—U—A—CO—B— group.
  • This peptide formation reaction can employ a method known per se.
  • Commonly available techniques include N, N'-dicyclohexylcarpoimide (DCC), water-soluble ruposimid hydrochloride (1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride ( EDC ⁇ HC 1))) as a condensing agent, active ester method, mixed acid anhydride method, and the like.
  • DCC N'-dicyclohexylcarpoimide
  • EDC ⁇ HC 1 water-soluble ruposimid hydrochloride
  • active ester method ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride
  • the reaction is carried out in an inert solvent at a temperature of from 0 to under heating. Suitable solvents include black form, getyl ether, N, N-dimethylform Amides, ethyl acetate, dichlor
  • the active ester method comprises reacting the above compound [6] with p-12-trophenol, thiophenol, p-nitrothiophenol, N-hydroxysuccinimide and the like in an inert solvent in the presence of DCC.
  • an ester with N-hydroxysuccinimide), and without isolation or isolation further react with the above deprotected product in an inert solvent at 0 to 4 (TC reaction). It forms a peptide bond.
  • the compound [6] and an acid halide are prepared in an inert solvent in the presence of a tertiary amine (eg, pyridine, triethylamine).
  • a mixed acid anhydride is formed by reacting an acid derivative (eg, ethyl ethyl chloroformate, isobutyl chloroformate) at 0 ° C. to 40 ° C., and the mixed acid anhydride is further converted to the above deprotected compound. With 0 ° C. to 40 ° C. to form peptide bonds.
  • the DCC method is carried out in the presence or absence of the above-mentioned tertiary amine such as triethylamine in an inert solvent, or a suitable additive (for example, 1-hydroxybenzotriazole (HOBt), N-hydroxy-5— Under the conditions of addition or non-addition of norbornene-2,3-dicarboxylic acid imide (HONB)), the above deprotected product is reacted with [6] using DCC or EDCHC1 as a condensing agent. It forms the desired disulfide bonds.
  • a suitable additive for example, 1-hydroxybenzotriazole (HOBt), N-hydroxy-5—
  • HONB norbornene-2,3-dicarboxylic acid imide
  • the final target compound [1] is obtained by oxidizing the alcohol compound represented by the general formula [7] obtained in the above reaction (C) using an appropriate oxidizing agent. Similarly, the final target compound [1] can be obtained by oxidizing the compound [8] or the compound [I 1] described later.
  • This reaction is carried out, for example, in an inert solvent such as benzene, methylene chloride, N, N-dimethylformamide at 0 ° C. to reflux temperature, preferably at 0 ° C. to room temperature, in the presence of peroxidic sieve.
  • an inert solvent such as benzene, methylene chloride, N, N-dimethylformamide
  • pyridinium chromate chromate Dimethyl sulfoxide is used in the presence of oxalyl chloride and triethylamine at a temperature of 180 ° C to room temperature, preferably 180 ° C to 0 ° C, in an inert solvent such as methylene chloride using pyridinium dichromate.
  • DCC in the presence of pyridine, trifluoroacetic acid, dimethyl sulfoxide at 0 ° C to room temperature in the presence or absence of an inert solvent (eg, benzene) or in the absence of an inert solvent (eg, benzene)
  • an inert solvent eg, benzene
  • a compound in which X is a zeo atom is oxidized using a peracid such as m-chloroperbenzoic acid, and a sulfoxide derivative represented by the general formula [8] It is what gains the body. Specifically, 1 equivalent or 2 equivalents of m-chloroperbenzoic acid at 120 ° C to reflux temperature, preferably 0 ° C to room temperature, in an inert solvent such as methylene chloride, chloroform and benzene. By using, a sulfoxide form or a sulfone form can be obtained, respectively.
  • X is a compound represented by the general formula [5] is NH, and using methods known in peptide chemistry, is intended to obtain compound by introducing Amino protecting group R 8 to [9].
  • Various amino protecting groups R 8 can be considered.
  • R 6 an acid for de-B 0 c conversion in the next reaction ([9] ⁇ [10]) is used. It must be stable to the processing, for example, formyl group, trifluoroacetyl group, etc., which are an acyl-type protecting group, and 9-fluorenylmethyloxycarbonyl group, which is a urethane-type protecting group, and methylsulfonylethyl.
  • an oxycarbonyl group formyl group, trifluoroacetyl group, etc., which are an acyl-type protecting group, and 9-fluorenylmethyloxycarbonyl group, which is a urethane-type protecting group, and methylsulfonylethyl.
  • the introduction of these protecting groups can be achieved by a known method (“Basic and Experimental Peptide Synthesis”, Izumiya et al., Maruzen).
  • introduction of a trifluoroacetyl group is carried out by reaction with trifluoroacetic acid ethyl ester in a solvent such as methanol in the presence of a tertiary amine such as triethylamine at 0 ° C. to room temperature, preferably room temperature.
  • a tertiary amine such as triethylamine at 0 ° C. to room temperature, preferably room temperature.
  • R 8 may be introduced.
  • Amino method for removing the protecting group R 8 varies depending on the type of protecting group can be used Oite methods known to peptide chemistry. For example, triflates Ruo b dividing the acetyl groups removed by the solvent such as methanol, potassium carbonate as a base, sodium carbonate, using a completion Nmonia, 0 e C to the reflux temperature, preferably takes place at room temperature.
  • the solvent such as methanol, potassium carbonate as a base, sodium carbonate
  • a completion Nmonia 0 e C to the reflux temperature
  • R 7 -B-COOH R 7 is an appropriate amino protecting group
  • R 7 is subjected to a condensation reaction with the compound [5] in the same manner as in the reaction (C) to obtain a compound represented by the general formula [17].
  • the compound shown is obtained.
  • the desired compound [7] can be obtained by reacting with the compound represented by WUA-COOH (when A is —CHR 1 —).
  • a in the former one 0, in the case of -NR 2 scratch, for example, W- U- A- H 1, 4 one Jiokisan, in a suitable solvent such as tetrahydrofuran, tertiary Amin such Toriechiruamin
  • phosgene, trichloromethylchloroformate, carbonyldiimidabour and the like at ⁇ 20 ° C. to room temperature in the presence of and then reacting with the deprotected compound of compound [17].
  • a in the latter is —CHR 1 —
  • the deprotected compound of compound [17] is converted to W—U—A—COOH or the corresponding acid chloride using the method described in the aforementioned reaction (C). Achieved by performing a condensation reaction with W—U—A—COC1.
  • the compound [9] is converted to the compound represented by the general formula [19] in the same manner as in the above reaction (K), and then the reaction (L) is performed in the same manner as above. As a result, the desired compound [10] can be prepared.
  • optically active sulfinyl compound represented by can be produced according to the following steps.
  • the compound represented by the general formula [12] was prepared by the method described in the literature (P. Pitchen et.al., J. Am. Chem. Soc., 106, 8188-8193 (1984); SH Zhao et. Al., Tetrahedron) .43.5135-5144 (1987)) to obtain an optically active sulfoxide represented by the general formula [13].
  • This reaction is, for example, methylene chloride, 1, 2-titanium Te Bok La isopropoxide Boki Sid in a solvent such as Jikuroroetan, the presence of an optically active tartaric acid Jechiru and water, 0 e C or less, preferably from one 4 0 ° C At 20 ° C, use tert-butyl hydroperoxide or cumene hydroperoxide.
  • An optically active sulfoxide represented by the general formula [13] is treated with a base to give a corresponding carbodione, which is converted into an ester or compound represented by the general formula [14] (R 9 represents a carboxyl protecting group) [14] condensation with an aldehyde represented by the general formula [15] derived by a known method to obtain an optically active sulfinyl compound represented by the general formula [1] or [16], respectively. .
  • the reaction is carried out, for example, by converting the optically active sulfoxide [13] into an inert organic solvent such as THF, 1,4-dioxane at a temperature of from 178 to room temperature, preferably at a reaction temperature of 0 ° C.
  • N-protected prolinal [2], HX-R [4], Q-COOH [6], IT-B-COOH, W—U—A—H, W—U—A—C00H , CH 3 S—R [12] and proline ester [18] can be obtained as known substances or can be obtained by a known method from a known syrup. It can be easily derived and synthesized.
  • a protecting group may be introduced at an appropriate stage as necessary, and a suitable step (preferably, the final step reaction (D) or reaction (J)) may be carried out. Before ()), the protecting group may be removed.
  • Simplification and purification of the thus obtained compound represented by the general formula [1] from the reaction mixture can be carried out by using any means commonly used in the field of synthetic organic chemistry. For example, it can be isolated and purified by methods such as column chromatography, solvent extraction, and recrystallization. The singulation and purification may be performed for each reaction, or may be performed after completion of some reactions.
  • Each of the above series of compounds has one to three asymmetric centers in the molecule.
  • the configuration of each asymmetric center is either R or S, or a mixture thereof. It may be.
  • Each optically active substance can be obtained by using an optically active compound as a starting material or by purifying the obtained diastereomer mixture by a method such as column chromatography or recrystallization.
  • the compound of the present invention is used as a pharmaceutical, it is usually administered systemically or locally, orally or parenterally.
  • the dosage varies depending on age, body weight, symptoms, therapeutic effect, administration method, etc., but is usually in the range of lmg to 100mg at a time per adult, once or several times daily. It is administered orally or parenterally once per adult per day in the range of 0.2 rag to 2 nig.
  • the compound of the present invention is used in the form of a solid composition or liquid composition for oral administration or an injection or suppository for parenteral administration.
  • Solid compositions for oral administration include tablets, pills, capsules, powders, granules and the like.
  • one or more active substances are used in admixture with at least one inert diluent, and may include excipients, binders, lubricants, disintegrants, You may contain a solubilizing agent, a stabilizer, etc. Tablets or pills may be coated with a film of a gastric or enteric material, if necessary.
  • the capsules include hard capsules and soft capsules.
  • Liquid compositions for oral administration include solutions, emulsions, suspensions, syrups, and elixirs. Such liquid compositions will include commonly used inert diluents, as well as auxiliary agents such as wetting agents and suspending agents, sweetening agents, flavoring agents, flavoring agents, preservatives An agent may be contained.
  • Injections for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
  • one or more active substances are used in a mixture with at least one inert aqueous diluent or inert non-aqueous diluent. It may contain adjuvants such as preservatives, wetting agents, emulsifiers, dispersants, stabilizers and solubilizers. These are usually sterilized by filtration (such as a bacteria-retaining filter), blending of a bactericide or gamma-irradiation, or after these treatments, solidified by a method such as freeze-drying, and used immediately before use. Sterile water or a sterile injectable diluent is used.
  • the extract was washed with saturated saline, dried over anhydrous sodium sulfate, and concentrated.
  • the residue was purified by silica gel column chromatography (eluent: ethyl hexane monoacetate) to obtain two diastereomers of the title compound, 3.12 g of a low-polar compound and 1.28 g of a high-polar compound (both of them).
  • the three-dimensional structure of the epoxy part has not been determined). In the following reactions, a low-polar substance was used.
  • (2S) 1 2 [1-Hydroxy-2- (4-methoxyphenoxy) ethyl] 1 1 CN- (phenoxyacetyl) 1; L-prolyl] pyrrolidine (478 mg) in DMSO (3.5 m 1) And benzene (1.5 ml) and triethylamine (0.7 ml) were added. After the mixture was cooled on ice, iodopyridine complex (730 mg) was added little by little, and triethylamine (0.25 m 1) was added to keep the reaction solution neutral. After stirring at 5 to 10 for 1 hour, the reaction solution was poured into ice water and extracted with ethyl acetate.
  • Example 5 Prepared in the same manner as in a) of Example 5 with trichloromethyl chromate formate (0.37 ml), N-benzylglycineethyl ester (1.2 ml) and c) of Example 1 (2S).
  • L-prolyl) 12- (1-hydroxy-2-phenyloxethyl) pyrrolidine obtained by treating with hydrochloric acid (2S) -2- (1-hydroxyl)
  • the title compound (2.12 g) was obtained using 2-phenoxetyl) 1-111 (L-prolyl) pyrrolidine hydrochloride (1.75 g).
  • the proline derivative represented by the general formula [1] according to the present invention was tested for its prolyl endopeptidase inhibitory activity and inhibitory activity against various proteases in an in vitro system.
  • the mixture (100-1) was pre-cubated at 0.30 ° C for 30 minutes (using the method described in (1980)).
  • 125 1 was added and incubated at 30 ° C for 1 hour. Stop the reaction by immersing the reaction mixture in ice (0 ° C).
  • Inhibition rate (%) 1 x 1 0 0
  • the compound of the present invention was found to have excellent inhibitory activity on prolylendopeptidase.
  • the method for measuring the activity of inhibiting various proteases except for prolylendopeptidase and the method for calculating the inhibition rate are as follows. Measurement of Hata trypsin inhibitory activity
  • a 5 OmM Tris-HCl buffer (pH 8.0) was used as the measurement buffer, and a 0.2 M buffer solution of leucine aminopeptidase (derived from Bushu Kidney, manufactured by Sigma) was used as the enzyme solution.
  • a 0.2 M buffer solution of leucine aminopeptidase derived from Bushu Kidney, manufactured by Sigma
  • 20 0 / M the same buffer solution of 7-mouth Ishiru 4 one Mechirukumari N'ami de (manufactured Ltd. peptide Institute) as, in the same manner as above, each fluorescence intensity was measured d 2 and d 3.
  • I mM Tris-HCl buffer pH 8.5
  • 0.2% elastase derived from pig kidney, manufactured by Sigma
  • substrate solution 200 Iv of 7- (N-succinylol-lanilupol-lilualanil)-4--methylcoumarinamide (manufactured by Peptide Research Laboratories) [Use the same buffer solution as above, in the same manner, each fluorescence intensity was measured e 2 and e 3. Measurement of catabstin B inhibitory activity
  • Fluorescence intensity X measured in this way, (the chi b, c, d, representative of e and f) chi 2 and chi 3 used, and the percent inhibition for various proteolytic enzymes was calculated by the following equation.
  • the novel proline derivative represented by the general formula [1] has a very strong inhibitory activity on prolyl peptidase, but has trypsin, chymotrypsin, leucine aminopeptidase, elastase, cathepsin B, etc. It has been shown that it does not act at all on the protease, which degrades and inactivates hormones in the brain containing proline residues and neurotransmitters such as TRH, substance P, neurotensin, and vasobrescine. It is considered to be a compound that specifically suppresses the conversion.
  • the compound of the present invention can be expected to make an effective contribution to the improvement of symptoms of various diseases mediated by hormones and neurotransmitters, and as an anti-dementia drug or an anti-amnesic agent that directly acts on the core symptoms of dementia, Alzheimer's disease It can be used for prevention and Z or treatment of dementia and amnesia including

Abstract

L'invention se rapporte à un dérivé de proline représenté par la formule générale (I), où A représente -O-, -CHR1- ou -NR2-, R1 représentant hydrogène ou hétérocycle et R2 représentant alcoxycarbonyle inférieur-alkyle inférieur; W représente phényle qui peut être substitué par halogène, alkyle inférieur ou alcoxy inférieur, adamantyle, alkyle inférieur ou hétérocycle; U représente -O-, -S-, -NH- ou -CHR5-, R5 représentant hydrogène ou alcoxycarbonyle inférieur; X représente -S-, -SO-, -SO¿2?-, -O- ou -NH-; D représente benzène ou hétérocycle; et Y et Z, qui peuvent être identiques ou différents l'un de l'autre, représentent chacun hydrogène, halogène, alkyle inférieur éventuellement fluoré, amino, nitro, hydroxy ou alcoxy inférieur. Ce dérivé possède un pouvoir inhibiteur spécialement puissant contre la prolyle endopeptidase et il inhibe la décomposition et l'inactivation de la TRH (hormone thyréolibérine), de la substance P, de la neurotensine, de la vasopressine, etc.. Ce dérivé peut par conséquent être utilisé pour prévenir et/ou traiter les états de démence, tels que la maladie d'Alzheimer et l'amnésie.
PCT/JP1992/001711 1990-07-27 1992-12-25 Derive de proline WO1993013065A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US08/026,311 US5506256A (en) 1990-07-27 1993-02-26 Proline derivatives possessing prolyl endopeptidase-inhibitory activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP3/361355 1991-12-27
JP3361355A JPH05186498A (ja) 1991-12-27 1991-12-27 プロリン誘導体

Publications (1)

Publication Number Publication Date
WO1993013065A1 true WO1993013065A1 (fr) 1993-07-08

Family

ID=18473247

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1992/001711 WO1993013065A1 (fr) 1990-07-27 1992-12-25 Derive de proline

Country Status (2)

Country Link
JP (1) JPH05186498A (fr)
WO (1) WO1993013065A1 (fr)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996018643A1 (fr) * 1994-12-13 1996-06-20 Novartis Ag Antagonistes de la tachykinine
US5536737A (en) * 1992-11-20 1996-07-16 Japan Tobacco Inc. Compound having prolyl endopeptidase inhibitory activity and pharmaceutical use thereof
WO1998035960A1 (fr) * 1997-02-14 1998-08-20 Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. Inhibiteurs de prolylendopeptidase
WO2004098591A2 (fr) 2003-05-05 2004-11-18 Probiodrug Ag Inhibiteurs de glutaminyl-cyclase
WO2005049027A2 (fr) 2003-11-03 2005-06-02 Probiodrug Ag Combinaisons utiles au traitement de troubles neuronaux
WO2005075436A2 (fr) 2004-02-05 2005-08-18 Probiodrug Ag Nouveaux inhibiteurs de la glutaminyl-cyclase
WO2008055945A1 (fr) 2006-11-09 2008-05-15 Probiodrug Ag Dérivés 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one utiles en tant qu' inhibiteurs de la glutaminyl-cyclase dans le traitement des ulcères, du cancer et d'autres maladies
WO2008065141A1 (fr) 2006-11-30 2008-06-05 Probiodrug Ag Nouveaux inhibiteurs de glutaminylcyclase
WO2008104580A1 (fr) 2007-03-01 2008-09-04 Probiodrug Ag Nouvelle utilisation d'inhibiteurs de la glutaminyl cyclase
WO2011029920A1 (fr) 2009-09-11 2011-03-17 Probiodrug Ag Dérivés hétérocycliques en tant qu'inhibiteurs de glutaminyle cyclase
WO2011107530A2 (fr) 2010-03-03 2011-09-09 Probiodrug Ag Nouveaux inhibiteurs
WO2011110613A1 (fr) 2010-03-10 2011-09-15 Probiodrug Ag Inhibiteurs hétérocycliques de la glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (fr) 2010-04-21 2011-10-27 Probiodrug Ag Nouveaux inhibiteurs
WO2012123563A1 (fr) 2011-03-16 2012-09-20 Probiodrug Ag Dérivés de benzimidazole en tant qu'inhibiteurs de la glutaminyl cyclase
EP2865670A1 (fr) 2007-04-18 2015-04-29 Probiodrug AG Dérivés de thio-urée utilisés comme inhibiteurs de la glutaminyl cyclase
EP3461819A1 (fr) 2017-09-29 2019-04-03 Probiodrug AG Inhibiteurs de la glutaminyl-cyclase

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63258852A (ja) * 1987-04-11 1988-10-26 ヘキスト・アクチエンゲゼルシヤフト 新規なピロリジン‐２‐（１，３‐ジカルボニル）誘導体
JPS6442465A (en) * 1987-08-07 1989-02-14 Wakunaga Pharma Co Ltd N-acylprolylpyrrolidine derivative, production and use thereof
JPS6442475A (en) * 1987-08-08 1989-02-14 Kissei Pharmaceutical Thiazolidine derivative

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63258852A (ja) * 1987-04-11 1988-10-26 ヘキスト・アクチエンゲゼルシヤフト 新規なピロリジン‐２‐（１，３‐ジカルボニル）誘導体
JPS6442465A (en) * 1987-08-07 1989-02-14 Wakunaga Pharma Co Ltd N-acylprolylpyrrolidine derivative, production and use thereof
JPS6442475A (en) * 1987-08-08 1989-02-14 Kissei Pharmaceutical Thiazolidine derivative

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5536737A (en) * 1992-11-20 1996-07-16 Japan Tobacco Inc. Compound having prolyl endopeptidase inhibitory activity and pharmaceutical use thereof
WO1996018643A1 (fr) * 1994-12-13 1996-06-20 Novartis Ag Antagonistes de la tachykinine
WO1998035960A1 (fr) * 1997-02-14 1998-08-20 Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. Inhibiteurs de prolylendopeptidase
WO2004098591A2 (fr) 2003-05-05 2004-11-18 Probiodrug Ag Inhibiteurs de glutaminyl-cyclase
EP2338490A2 (fr) 2003-11-03 2011-06-29 Probiodrug AG Combinaisons utiles pour le traitement de désordres neuronales
WO2005049027A2 (fr) 2003-11-03 2005-06-02 Probiodrug Ag Combinaisons utiles au traitement de troubles neuronaux
WO2005075436A2 (fr) 2004-02-05 2005-08-18 Probiodrug Ag Nouveaux inhibiteurs de la glutaminyl-cyclase
US7897633B2 (en) 2004-02-05 2011-03-01 Probiodrug Ag Inhibitors of glutaminyl cyclase
WO2008055945A1 (fr) 2006-11-09 2008-05-15 Probiodrug Ag Dérivés 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one utiles en tant qu' inhibiteurs de la glutaminyl-cyclase dans le traitement des ulcères, du cancer et d'autres maladies
WO2008065141A1 (fr) 2006-11-30 2008-06-05 Probiodrug Ag Nouveaux inhibiteurs de glutaminylcyclase
WO2008104580A1 (fr) 2007-03-01 2008-09-04 Probiodrug Ag Nouvelle utilisation d'inhibiteurs de la glutaminyl cyclase
EP2481408A2 (fr) 2007-03-01 2012-08-01 Probiodrug AG Nouvelle utilisation d'inhibiteurs glutaminyle cyclase
EP2865670A1 (fr) 2007-04-18 2015-04-29 Probiodrug AG Dérivés de thio-urée utilisés comme inhibiteurs de la glutaminyl cyclase
WO2011029920A1 (fr) 2009-09-11 2011-03-17 Probiodrug Ag Dérivés hétérocycliques en tant qu'inhibiteurs de glutaminyle cyclase
WO2011107530A2 (fr) 2010-03-03 2011-09-09 Probiodrug Ag Nouveaux inhibiteurs
WO2011110613A1 (fr) 2010-03-10 2011-09-15 Probiodrug Ag Inhibiteurs hétérocycliques de la glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (fr) 2010-04-21 2011-10-27 Probiodrug Ag Nouveaux inhibiteurs
WO2012123563A1 (fr) 2011-03-16 2012-09-20 Probiodrug Ag Dérivés de benzimidazole en tant qu'inhibiteurs de la glutaminyl cyclase
EP3461819A1 (fr) 2017-09-29 2019-04-03 Probiodrug AG Inhibiteurs de la glutaminyl-cyclase

Also Published As

Publication number Publication date
JPH05186498A (ja) 1993-07-27

Similar Documents

Publication Publication Date Title
CA2149892C (fr) Inhibiteur et applications pharmaceutiques de cette substance
WO1993013065A1 (fr) Derive de proline
EP0461677B1 (fr) Dérivés de thiazolidine
EP0277588B1 (fr) Dérivés du prolinal
US5118811A (en) Amino acid derivatives possessing prolyl endopeptidase-inhibitory activities
US20020107181A1 (en) Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising N-cyclic P2 moieties
US5506256A (en) Proline derivatives possessing prolyl endopeptidase-inhibitory activity
SK25099A3 (en) Substituted cyclic amine metalloprotease inhibitors
JP4237824B2 (ja) 新規なアミノ酸誘導体およびトロンビン阻害剤としてのその使用
KR20060085248A (ko) Ｃ형 간염 바이러스 ｎｓ3 세린 프로테아제의마크로사이클릭 억제제
JP2002047264A (ja) アミノアルキルベンゼン化合物
CZ421297A3 (cs) Nové inhibitory thrombinu, jejich příprava a použití
JPH07242616A (ja) 抗血栓剤としてのペプチドアルデヒド類
WO1998001133A1 (fr) Inhibiteurs de la resorption osseuse
CA2048010C (fr) Derives de la proline
JPH05201970A (ja) 新規プロリン誘導体
JPH0820597A (ja) トロンビン阻害作用を有する複素環カルボニル化合物
KR940003297B1 (ko) 1,3,2-디옥사티오렌옥시드 유도체
EP0618193A1 (fr) Dérivés bicycliques azotés, en tant qu'inhibiteurs de prolyl-endopeptidase
WO2002096892A1 (fr) Composes derives d'oxadiazole et medicaments contenant ces composes comme ingredient actif
JPH0525125A (ja) 新規なプロリン誘導体
US6417161B1 (en) Amino acid amidinohydrazones, alkoxyguanidines and aminoguanidines as protease inhibitors
KR20030024797A (ko) 메탈로프로테아제 억제제로서 사용하기 위한피롤리딘-2-카복실산 하이드라지드 유도체
Augustyns et al. Synthesis of peptidyl acetals as inhibitors of prolyl endopeptidase
FR2487341A1 (fr) Tripeptides inhibiteurs de l'enzyme de transformation de l'angiotensine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA